AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15078044 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigating through a virtual simulation
Number of subjects: 0
Study 11921832 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter Paper Haemagglutination Inhibition (FPHAI)
Number of subjects: 165
Study 11921832 — intervention group
Group type: COMPARATOR
Intervention: Serum Haemagglutination Inhibition (HAI)
Number of subjects: 165
Study 9459045 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg enteric-coated tablet taken under fasting conditions
Number of subjects: 57
Study 9459045 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg enteric-coated tablet taken before breakfast
Number of subjects: 57
Study 9459045 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg enteric-coated tablet taken after breakfast
Number of subjects: 57
Study 9459045 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of fasting and after breakfast regimens
Number of subjects: 57
Study 9459045 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of fasting and before breakfast regimens
Number of subjects: 57
Study 7932957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical heart valves
Number of subjects: 72
Study 7932957 — intervention group
Group type: COMPARATOR
Intervention: Biological valves
Number of subjects: 72
Study 7932957 — intervention group
Group type: COMPARATOR
Intervention: Mechanical valves
Number of subjects: 72
Study 3070474 — intervention group
Group type: EXPERIMENTAL
Intervention: metaproterenol (1,300 micrograms) with Inspir‐Ease spacer
Number of subjects: 13
Study 3070474 — intervention group
Group type: EXPERIMENTAL
Intervention: metaproterenol (1,300 micrograms) with Aerochamber spacer
Number of subjects: 13
Study 3070474 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 31552590 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus MVr
Number of subjects: 80
Study 31552590 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 80
Study 29650371 — intervention group
Group type: EXPERIMENTAL
Intervention: Turo group (8-week Turo training program, 60-minute sessions twice a week)
Number of subjects: 32
Study 29650371 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (no additional treatment during the same period)
Number of subjects: 32
Study 28329919 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 0
Study 28329919 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0
Study 26244978 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Cytopheretic Device (SCD) therapy
Number of subjects: 134
Study 26244978 — intervention group
Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT) alone
Number of subjects: 134
Study 24257178 — intervention group
Group type: EXPERIMENTAL
Intervention: HUA group (76 cases)
Number of subjects: 157
Study 24257178 — intervention group
Group type: COMPARATOR
Intervention: NUA group (81 cases)
Number of subjects: 157
Study 21726427 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP plus intravitreal ranibizumab (IVR)
Number of subjects: 40
Study 21726427 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 40
Study 18362316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 2% CPP-ACP and 450-ppm-F
Number of subjects: 0
Study 18362316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 2% CPP-ACP
Number of subjects: 0
Study 18362316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 2% CPP-ACP plus 1100 ppm F
Number of subjects: 0
Study 16652079 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation-assisted partial turbinoplasty
Number of subjects: 60
Study 16652079 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted partial turbinoplasty
Number of subjects: 60
Study 12785025 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystacide applied around and on the ulcer for 10 days
Number of subjects: 20
Study 12785025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10819810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol 9 suppository (150 mg, intravaginally for 3 consecutive nights)
Number of subjects: 46
Study 10819810 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (2 g, single oral dose)
Number of subjects: 46
Study 8830962 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 0
Study 8830962 — intervention group
Group type: COMPARATOR
Intervention: Knitted viscose dressing
Number of subjects: 0
Study 8830962 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 0
Study 1447105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (10 degrees C)
Number of subjects: 19
Study 6090368 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (2.1-2.7 g/m2 per treatment day, given 4 hours before irradiation)
Number of subjects: 45
Study 6090368 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 45
Study 31283562 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence Risk Score (RRS) for patients with symptomatic tumors, tumors >2 cm, Ki67 >3%, and lymph node (+) disease.
Number of subjects: 1006
Study 31283562 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance intervals proposed based on RRS.
Number of subjects: 1006
Study 27633492 — intervention group
Group type: COMPARATOR
Intervention: Control condition (informed they would perform 12 MVCs)
Number of subjects: 14
Study 27633492 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown condition (not informed of the number of MVCs to be completed, but stopped after 12)
Number of subjects: 14
Study 27633492 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception condition (instructed to complete 6 MVCs, however, after the sixth repetition performed another 6 MVCs)
Number of subjects: 14
Study 25688059 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus Bev (7.5 mg/kg)
Number of subjects: 147
Study 25688059 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 147
Study 25688059 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus Bev
Number of subjects: 147
Study 23724512 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal three-dimensional sonohysterography (3D SHSG)
Number of subjects: 44
Study 23724512 — intervention group
Group type: COMPARATOR
Intervention: Outpatient hysteroscopy
Number of subjects: 44
Study 21036492 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed counseling and printed materials (n=810)
Number of subjects: 2032
Study 21036492 — intervention group
Group type: COMPARATOR
Intervention: Standard-care counseling and printed materials (n=1222)
Number of subjects: 2032
Study 21036492 — intervention group
Group type: COMPARATOR
Intervention: Standard-care messages (n=1222)
Number of subjects: 2032
Study 21036492 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages (n=810)
Number of subjects: 2032
Study 19236580 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal acid perfusion (0.2 N, 5 mL min(‐1))
Number of subjects: 12
Study 19236580 — intervention group
Group type: COMPARATOR
Intervention: Saline perfusion
Number of subjects: 12
Study 19236580 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal acid perfusion
Number of subjects: 12
Study 16251263 — intervention group
Group type: COMPARATOR
Intervention: Arm cycling
Number of subjects: 0
Study 16251263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic contraction
Number of subjects: 0
Study 14639083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms (heaviness in past year, swelling now, numbness in past year)
Number of subjects: 80
Study 14639083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms (heaviness in past year, swelling now)
Number of subjects: 80
Study 14639083 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbness in past year
Number of subjects: 80
Study 10953178 — intervention group
Group type: COMPARATOR
Intervention: Control-stable
Number of subjects: 129
Study 10953178 — intervention group
Group type: COMPARATOR
Intervention: Control-decliner
Number of subjects: 129
Study 10953178 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-stable
Number of subjects: 129
Study 10953178 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-decliner
Number of subjects: 129
Study 10953178 — intervention group
Group type: EXPERIMENTAL
Intervention: AD
Number of subjects: 129
Study 8610912 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine 1 mg/kg
Number of subjects: 100
Study 8610912 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg
Number of subjects: 100
Study 8610912 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.2 mg/kg
Number of subjects: 100
Study 8610912 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study 1442316 — intervention group
Group type: EXPERIMENTAL
Intervention: CF neonatal screening
Number of subjects: 0
Study 1442316 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 4060201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospidin combined with preoperative radiotherapy
Number of subjects: 27
Study 4060201 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy alone
Number of subjects: 27
Study 31703717 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 19
Study 29508689 — intervention group
Group type: COMPARATOR
Intervention: Normal bread
Number of subjects: 28
Study 29508689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread treated with 0.8% ANPEP
Number of subjects: 28
Study 29508689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread treated with 1% ANPEP
Number of subjects: 28
Study 29508689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein bread made from biscuit flour
Number of subjects: 28
Study 29508689 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 28
Study 29508689 — intervention group
Group type: EXPERIMENTAL
Intervention: ANPEP treatment
Number of subjects: 28
Study 26663152 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar (150 µg once daily)
Number of subjects: 40
Study 26663152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25193295 — intervention group
Group type: EXPERIMENTAL
Intervention: LA roof ablation (LARA-1)
Number of subjects: 120
Study 25193295 — intervention group
Group type: COMPARATOR
Intervention: PV isolation (LARA-2)
Number of subjects: 120
Study 22472180 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography followed by surgical staging if negative (n = 123)
Number of subjects: 241
Study 22472180 — intervention group
Group type: COMPARATOR
Intervention: Surgical staging alone (n = 118)
Number of subjects: 241
Study 22472180 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography strategy
Number of subjects: 241
Study 22472180 — intervention group
Group type: COMPARATOR
Intervention: Surgical staging alone
Number of subjects: 241
Study 20937922 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation training (intervention group)
Number of subjects: 170
Study 20937922 — intervention group
Group type: COMPARATOR
Intervention: Skin cancer prevention training (control group)
Number of subjects: 170
Study 19092244 — intervention group
Group type: EXPERIMENTAL
Intervention: Crofelemer 500 mg
Number of subjects: 242
Study 19092244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 19092244 — intervention group
Group type: EXPERIMENTAL
Intervention: Crofelemer 125 mg
Number of subjects: 242
Study 19092244 — intervention group
Group type: EXPERIMENTAL
Intervention: Crofelemer 250 mg
Number of subjects: 242
Study 16145414 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin controlled release gastrointestinal therapeutic system formulation (4 mg once daily)
Number of subjects: 211
Study 16145414 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride (20 mg once daily) plus doxazosin controlled release gastrointestinal therapeutic system formulation
Number of subjects: 211
Study 11827582 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement of the left or right ethmoid cavity
Number of subjects: 17
Study 11827582 — intervention group
Group type: COMPARATOR
Intervention: No debridement
Number of subjects: 17
Study 10418762 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697 (4 x 4 tablets over 48 h)
Number of subjects: 103
Study 10418762 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine (3 x 2 tablets over 12 h with a second course 1 week later)
Number of subjects: 103
Study 7736317 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 13
Study 7736317 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 13
Study 1828348 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (80 mmol/day KCl for 4 days)
Number of subjects: 0
Study 7027988 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy package
Number of subjects: 0
Study 7027988 — intervention group
Group type: COMPARATOR
Intervention: Insight-oriented therapy
Number of subjects: 0
Study 29470317 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte Filter
Number of subjects: 60
Study 29470317 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 28234437 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drugs (mood stabilizer plus adjunctive antidepressant)
Number of subjects: 188
Study 28234437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 25975974 — intervention group
Group type: EXPERIMENTAL
Intervention: LipiView® ocular surface interferometer
Number of subjects: 20
Study 24067460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphurous thermal water (STW)
Number of subjects: 50
Study 24067460 — intervention group
Group type: EXPERIMENTAL
Intervention: S-based compound (NaSH)
Number of subjects: 50
Study 22288082 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuO2
Number of subjects: 28
Study 22288082 — intervention group
Group type: COMPARATOR
Intervention: Continuous-flow O2
Number of subjects: 28
Study 22288082 — intervention group
Group type: COMPARATOR
Intervention: CR-50
Number of subjects: 28
Study 19478215 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR 50 to 59 mL/min/1.73 m2
Number of subjects: 5494
Study 19478215 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR <50 mL/min/1.73 m2
Number of subjects: 5494
Study 19478215 — intervention group
Group type: COMPARATOR
Intervention: Optimal BP subjects without CKD
Number of subjects: 5494
Study 17224851 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 164
Study 17224851 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 164
Study 17224851 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study 12093952 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced use treatment (plaster cast on unimpaired arm for 1 month)
Number of subjects: 25
Study 12093952 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cast)
Number of subjects: 25
Study 12093952 — intervention group
Group type: COMPARATOR
Intervention: Crossover control group (received casts after 6 months)
Number of subjects: 25
Study 10624641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 3%
Number of subjects: 60
Study 10624641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 4%
Number of subjects: 60
Study 10624641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 5%
Number of subjects: 60
Study 10624641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 6%
Number of subjects: 60
Study 8745137 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE questionnaire
Number of subjects: 219
Study 8745137 — intervention group
Group type: COMPARATOR
Intervention: Other diagnostic tests (Alcohol Clinical Index, MCV, GGT, GOT/GPT, GGT/AP)
Number of subjects: 219
Study 1782716 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline gauze nasal packing
Number of subjects: 50
Study 1782716 — intervention group
Group type: COMPARATOR
Intervention: 30 Dexon mucosal suture
Number of subjects: 50
Study 1782716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 7284888 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 0
Study 7284888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (epidural)
Number of subjects: 0
Study 29788977 — intervention group
Group type: EXPERIMENTAL
Intervention: B'more Healthy Communities for Kids (BHCK) intervention
Number of subjects: 385
Study 29788977 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 385
Study 29788977 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase by 1 year
Number of subjects: 385
Study 28034987 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and specific neck exercises
Number of subjects: 50
Study 23260098 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated, humidified high-flow nasal cannulae (HHHFNC)
Number of subjects: 132
Study 23260098 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 132
Study 21613626 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocanalicular, high-pressure, 5-mm balloon catheter, endoscopic DCR
Number of subjects: 66
Study 21613626 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic DCR
Number of subjects: 66
Study 18436150 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial/behavioral intervention plus antidepressant
Number of subjects: 101
Study 18436150 — intervention group
Group type: COMPARATOR
Intervention: Usual care including antidepressants
Number of subjects: 101
Study 17138031 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic strain rate (SR) less than 2 s(‐1)
Number of subjects: 15
Study 17138031 — intervention group
Group type: COMPARATOR
Intervention: Systolic strain rate (SR) greater than 2 s(‐1)
Number of subjects: 15
Study 17138031 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed systolic strain rate (SR)
Number of subjects: 15
Study 15514496 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (ML) 10 mg
Number of subjects: 24
Study 15514496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 10426846 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally delivered urokinase
Number of subjects: 54
Study 10426846 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 54
Study 7552181 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler
Number of subjects: 13
Study 7552181 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer
Number of subjects: 13
Study 7552181 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerochamber
Number of subjects: 13
Study 2249707 — intervention group
Group type: EXPERIMENTAL
Intervention: Two periods of resource room instruction per day
Number of subjects: 67
Study 2249707 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultative services combined with in‐class instruction
Number of subjects: 67
Study 2249707 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultative services to classroom teachers
Number of subjects: 67
Study 2249707 — intervention group
Group type: COMPARATOR
Intervention: Resource room instruction (one period per day)
Number of subjects: 67
Study 7416947 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 7416947 — intervention group
Group type: COMPARATOR
Intervention: Control (without digoxin)
Number of subjects: 0
Study 31216321 — intervention group
Group type: EXPERIMENTAL
Intervention: modulated electro-hyperthermia (mEHT) administered 2/weekly immediately before external beam radiation
Number of subjects: 202
Study 31216321 — intervention group
Group type: COMPARATOR
Intervention: Control (chemoradiotherapy without mEHT)
Number of subjects: 202
Study 29675640 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) and whey protein supplementation
Number of subjects: 67
Study 29675640 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 67
Study 26876014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 26449
Study 26876014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26449
Study 24848812 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-gauge nonfenestrated catheter
Number of subjects: 205
Study 24848812 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge fenestrated catheter
Number of subjects: 205
Study 24848812 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge fenestrated catheter (third cohort)
Number of subjects: 205
Study 22169051 — intervention group
Group type: EXPERIMENTAL
Intervention: SC golimumab 100 mg every 4 weeks through week 20 (n = 33)
Number of subjects: 49
Study 22169051 — intervention group
Group type: COMPARATOR
Intervention: IV golimumab 2 mg/kg at weeks 0 and 12 (n = 16)
Number of subjects: 49
Study 22169051 — intervention group
Group type: EXPERIMENTAL
Intervention: SC golimumab
Number of subjects: 49
Study 22169051 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with concomitant MTX use
Number of subjects: 49
Study 22169051 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without concomitant MTX use
Number of subjects: 49
Study 22169051 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CL/F with and without MTX
Number of subjects: 49
Study 22169051 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerability of golimumab
Number of subjects: 49
Study 21132998 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex (Av)
Number of subjects: 90
Study 21132998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif (Re)
Number of subjects: 90
Study 21132998 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaferon (Be)
Number of subjects: 90
Study 18175518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol 2 mg daily
Number of subjects: 45
Study 18175518 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol 0.05 mg daily
Number of subjects: 45